News Headlines Article

Amgen and Novartis partnering on a drug that could prevent Alzheimer’s
Los Angeles Times

Thousand Oaks biotech firm Amgen Inc. is partnering with Swiss pharmaceutical giant Novartis to develop a drug that could slow or prevent Alzheimer’s disease. The companies, which announced the agreement Tuesday, will combine separate efforts on drugs that attack BACE, an enzyme that produces clusters of proteins called plaques believed to cause the brain disorder. Novartis was a step ahead of Amgen on the Alzheimer’s front, conducting clinical trials of an oral drug called CNP520. Amgen said it has “a number of preclinical candidates” in the Alzheimer’s field.